Premium
ZANUBRUTINIB, LENALIDOMIDE PLUS R‐CHOP (ZR 2 ‐CHOP) AS THE TREATMENT FOR DIFFUSED LARGE B‐CELL LYMPHOMA (DLBCL)
Author(s) -
Zhu H.,
Sha Y.,
Wu W.,
Chen R.,
Yang Y.,
Qiu J.,
Mi H.,
Peng C.,
Ding C.,
Wang Z.,
Fan L.,
Xu W.,
Li J.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.49_2881
Subject(s) - medicine , lenalidomide , rituximab , diffuse large b cell lymphoma , clinical endpoint , vincristine , prednisone , febrile neutropenia , oncology , adverse effect , surgery , lymphoma , neutropenia , cyclophosphamide , chemotherapy , clinical trial , multiple myeloma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom